PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

Life Science Newswire – Inceptua Group – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea® (ocriplasmin), a first-in-class pharmacological vitreolysis therapy approved for treatment of symptomatic vitreomacular adhesion (VMA) or vitreomacular traction (VMT) from Oxurion NV to Inceptua AB.

As marketing authorisation holder, Inceptua will assume full regulatory responsibility for Jetrea in the EU, Norway, Iceland, and Liechtenstein.

“We are pleased that the European Commission has granted approval for Inceptua to market Jetrea,” says Clive Whitcher, Executive Vice President and Head of Inceptua Pharma.

“For Inceptua Group Jetrea represents a unique opportunity to build on our commitment to specialty care and enhances our ability to ultimately help patients suffering from symptomatic vitreomacular adhesion or vitreomacular traction and support physicians specializing in eye diseases.”

Jetrea was launched in early 2013, and over 35,000(1) patients have been treated with the product to-date with real world clinical data(2-4) confirming efficacy and safety in a well identified group of patients suffering from symptomatic vitreomacular adhesion or vitreomacular traction.

VMT is caused by traction resulting from a persistent attachment of the vitreous humour (jelly-like material in the back of the eye) to the macula. The macula provides central vision that is needed for everyday tasks such as driving, reading and recognising faces. VMT can cause symptoms such as distorted and blurring of visual acuity or decreased vision. When the disease progresses, the traction may result in damage on the retina and risk of permanent visual impairment.

Inceptua Pharma — a part of Inceptua Group with offices across Europe, North America, and Asia — is an expert commercialization partner for Europe for rare disease and specialty care products with the expertise and capabilities to also supply unlicensed medicines globally.

About Inceptua Group — Pharma Company & Service Partner
Inceptua is a specialty pharmaceutical company and a premium global service partner.

Inceptua Pharma commercializes and market orphan and specialty care products and have also the expertise and capabilities to supply unlicensed medicines globally.

Inceptua Services supports pharma and biotech companies with global clinical trial comparator sourcing, packaging and labelling solutions, pre-approval and medicines access programs and consulting.

Inceptua partners with life science companies of all sizes, drawing on over 20 years of industry experience, and has global operations with local offices across Europe, North America, and Asia.
www.inceptua.com

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026